Skip to main content
. Author manuscript; available in PMC: 2016 Apr 27.
Published in final edited form as: Leuk Res. 2015 Feb 2;39(4):419–423. doi: 10.1016/j.leukres.2015.01.012

Figure 1.

Figure 1

Chr12 abnormalities in Philadelphia-negative myeloproliferative neoplasms and myelofibrosis. (A) Frequency of Chr12 abnormality in Ph-neg MPN and (expanded) type of MPN among Chr12 patients. (B) Frequency of Chr12 abnormality in MF and (expanded) Venn diagram of specific type of Chr12 abnormality in MF. Area of circle represents the relative frequency of abnormality. (C) Comparison of proportions of Chr12 and Non-Chr12 Ph-neg MPN patients who had MF, and MF patients who had PMF, PPMF, and PTMF. **p-value < 0.01; ***p-value < 0.001. (D) Comparison between survival of patients with and without Chr12 abnormalities, between combined patients with 12q13, 12q15 and 12q24 abnormalities and Non-Chr12 patients, and between 12q24 patients only versus Non-Chr12 patients. Ph-neg MPN, Philadelphia-chromosome negative myeloproliferative neoplasm; MF, myelofibrosis; HES, hypereosinophilic syndrome; PV, polycythemia vera; MPN-U, unspecified MPN; PMF, primary myelofibrosis; PPMF, post-polycythemia vera myelofibrosis; PTMF, post-thrombocytosis myelofibrosis.